VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Bristol-Myers Squibb Company vs Berkshire Hathaway Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisBerkshire Hathaway Inc.
BRK.B · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Berkshire Hathaway Inc.'s moat claims, evidence, and risks.
View BRK.B analysisComparison highlights
- Moat score gap: Berkshire Hathaway Inc. leads (64 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); Berkshire Hathaway Inc. has 11 segments (28.3% in Insurance (underwriting + investment income)).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs n/a.
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; Berkshire Hathaway Inc. has 17 across 4.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Berkshire Hathaway Inc.
Insurance (underwriting + investment income)
Insurance and reinsurance (property and casualty + life/health), including float-funded investing
Global
Consumers and businesses (policyholders) and insurers (reinsurance cedents)
Underwriter and reinsurer plus investment manager of float
28.3%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
Berkshire Hathaway Inc. strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Berkshire Hathaway Inc. segments
Full profile >Insurance (underwriting + investment income)
Competitive
BNSF Railway (freight rail transportation)
Oligopoly
Berkshire Hathaway Energy (regulated utilities, pipelines, renewables)
Monopoly
Industrial products manufacturing (PCC, Lubrizol, IMC, Marmon, etc.)
Oligopoly
Building products & housing (Clayton Homes, Shaw, Johns Manville, Benjamin Moore, etc.)
Competitive
Consumer products manufacturing (Duracell, Forest River, apparel/footwear, toys, etc.)
Competitive
Service businesses (FlightSafety, NetJets, TTI, Dairy Queen, etc.)
Competitive
Retailing businesses (Berkshire Hathaway Automotive, home furnishings, jewelry, See's, etc.)
Competitive
Pilot Travel Centers (travel centers + wholesale fuel marketing)
Oligopoly
McLane (wholesale distribution to convenience stores and restaurants)
Oligopoly
Holding company capital allocation and investing
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.